Affordable Access

Management of metastatic castration-resistant prostate cancer after first-line docetaxel

Publication Date
  • Rc0254 Neoplasms. Tumors. Oncology (Including Cancer)
  • Medicine


Although chemotherapy, based on docetaxel, is now established in the management of metastatic castration-resistant prostate cancer (mCRPC), until recently, there has been no treatment licensed for use in the second line in men whose disease progresses during or after docetaxel therapy. This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy.

There are no comments yet on this publication. Be the first to share your thoughts.